Biopharmaceutical group Arecor Therapeutics plc (AIM: AREC) announced on Wednesday that it presented promising Phase I trial results for its ultra-concentrated, ultra-rapid acting insulin, AT278, at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid.

The trial, conducted at the Medical University of Graz and Joanneum Research in Austria, demonstrated that AT278 (500 U/mL) outperforms NovoRapid (100 U/mL) in terms of glucose-lowering effects in Type 2 diabetes patients with high BMI.

AT278 showed a 1.7-fold higher glucose-lowering effect within the first 60 minutes compared to NovoRapid (p